This episode is dedicated to psychedelics research. It covers the recommendations from the US FDA guidance from Jul 2026 which clarifies the agency's expectations regarding the drug development and clinical trials design for psychedelics. In addition, there is an overview of the study design of a clinical trial with psilocybin used in treatment-resistant depression.